Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Menu

    Danicamtiv

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kardigan Shows Positive Ph 2a Danicamtiv Data in DCM at HFSA
    Kardigan Shows Positive Ph 2a Danicamtiv Data in DCM at HFSA

    29 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250929918876/en/Kardigan-Announces-Presentation-of-Positive-Phase-2a-Data-for-Danicamtiv-in-Patients-with-Dilated-Cardiomyopathy-at-HFSA-Annual-Scientific-Meeting-2025

    BUSINESSWIRE
    29 Sep 2025
    Share Share
    MyoKardia Doses First Patient in Phase 2 Clinical Trial of Danicamtiv in Genetic Dilated Cardiomyopathy
    MyoKardia Doses First Patient in Phase 2 Clinical Trial of Danicamtiv in Genetic Dilated Cardiomyopathy

    09 Sep 2020

    // PRESS RELEASE

    https://myokardia.gcs-web.com/news-releases/news-release-details/myokardia-doses-first-patient-phase-2-clinical-trial-danicamtiv

    PRESS RELEASE
    09 Sep 2020
    Share Share